Positive allosteric modulators (PAMs) of nicotinic acetylcholine (ACh) receptors (nAChRs) have potential clinical applications in the treatment of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity, and 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI) has been identified as a PAM selective for neuronal nAChRs containing the a4 subunit. In this report, we compare CMPI interactions with low-sensitivity (a4)3(b2)2 and high-sensitivity (a4)2(b2)3 nAChRs, and with muscle-type nAChRs. In addition, we use the intrinsic reactivity of [ 3 H]CMPI upon photolysis at 312 nm to identify its binding sites in Torpedo nAChRs. Recording from Xenopus oocytes, we found that CMPI potentiated maximally the responses of (a4) 3 (b2) 2 nAChR to 10 mM ACh (EC 10 ) by 400% and with an EC 50 of ∼1 mM. CMPI produced a left shift of the ACh concentration-response curve without altering ACh efficacy. In contrast, CMPI inhibited (∼35% at 10 mM) ACh responses of (a4) 2 (b2)